|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 7,635,704
United States Patent 7,635,704, titled "Anticipated binding and therapeutic modulation of neurokinin-1 receptors by a compound," issued to Glaxo Group Limited on December 22, 2009. The patent describes a specific chemical compound, Aprepitant (marketed as Emend), and its use in modulating neurokinin-1 (NK1) receptors. Aprepitant is an NK1 receptor antagonist. The patent's claims focus on the compound itself, pharmaceutical compositions containing it, and methods of treating conditions associated with NK1 receptor activity. The patent landscape reveals a core patent for Aprepitant with subsequent patents addressing formulation, manufacturing processes, and additional therapeutic uses, indicating a strategic approach to intellectual property protection by the assignee.
What is the Scope and Primary Subject of US Patent 7,635,704?
US Patent 7,635,704 claims a specific chemical entity, 5-([2R,3S]-2-((R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl-methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, hereinafter referred to as Aprepitant. This compound is characterized by its specific stereochemistry, which is critical for its pharmacological activity.
The patent's primary subject is the compound's ability to antagonize neurokinin-1 (NK1) receptors. NK1 receptors are G protein-coupled receptors that bind substance P, a neuropeptide implicated in various physiological and pathological processes, including pain, inflammation, and emesis. By blocking the binding of substance P to its receptor, Aprepitant inhibits NK1 receptor signaling.
The patent broadly covers:
- The Compound Itself: Claim 1 explicitly claims the chemical compound Aprepitant, defined by its specific chemical name and stereochemistry.
- Pharmaceutical Compositions: Claims extend to pharmaceutical compositions comprising Aprepitant and at least one pharmaceutically acceptable carrier. This allows for the protection of different dosage forms.
- Methods of Treatment: The patent claims methods of treating conditions associated with NK1 receptor activity. This includes, but is not limited to, preventing or treating chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). The method involves administering a therapeutically effective amount of Aprepitant.
The issued claims reflect a foundational patent for the active pharmaceutical ingredient (API) and its primary therapeutic indication.
What are the Key Claims Within US Patent 7,635,704?
US Patent 7,635,704 contains a series of claims that define the scope of protection granted to the assignee, Glaxo Group Limited. The claims are hierarchical, with independent claims defining the core invention and dependent claims narrowing the scope.
Independent Claims:
- Claim 1: Claims the specific chemical compound: 5-([2R,3S]-2-((R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl-methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one. This is the central claim covering the Aprepitant molecule.
- Claim 2: Claims a pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. This claim provides protection for formulated products.
- Claim 3: Claims a method for treating mammals suffering from nausea and vomiting comprising administering to the mammal a therapeutically effective amount of the compound of claim 1. This claim covers the primary therapeutic use for which Aprepitant is known.
Dependent Claims (Examples illustrating narrowing of scope):
- Claim 4: Claims the pharmaceutical composition of claim 2, wherein the composition is adapted for oral administration. This specifies a particular route of administration.
- Claim 5: Claims the pharmaceutical composition of claim 2, wherein the composition is adapted for intravenous administration. This covers another administration route, often for different formulations.
- Claim 6: Claims the method of claim 3, wherein the nausea and vomiting is chemotherapy-induced nausea and vomiting. This narrows the therapeutic indication to a specific clinical scenario.
- Claim 7: Claims the method of claim 3, wherein the nausea and vomiting is postoperative nausea and vomiting. This further specifies a distinct therapeutic application.
The claims are designed to protect the compound across its various forms and therapeutic applications, establishing a strong foundation for market exclusivity.
What is the Historical Context and Development of Aprepitant and its Related Patents?
Aprepitant's development represents a significant advancement in antiemetic therapy. Its identification and patenting were driven by the need for more effective treatments for nausea and vomiting, particularly in patients undergoing chemotherapy.
- Discovery and Early Patenting: The identification of Aprepitant as an NK1 receptor antagonist and its initial patenting occurred in the early to mid-1990s. Glaxo Wellcome (now part of GlaxoSmithKline) was instrumental in this research. Early patents, such as those filed around 1991-1992, would have covered the initial discovery of the compound class and specific examples, including Aprepitant. US Patent 7,635,704 is a later-expiring patent that specifically claims the compound and its method of use, often originating from a divisional application or continuation from an earlier parent application, potentially to extend patent protection or refine claims.
- Formulation and Manufacturing Patents: Following the initial API patent, subsequent patent filings typically focus on innovative formulations, improved manufacturing processes, and novel polymorphic forms. These patents are crucial for reinforcing market exclusivity and defending against generic competition. For Aprepitant, patents have been filed covering:
- Oral Formulations: Development of capsule and tablet forms (e.g., US Patent 8,004,306 B2 for a stable oral formulation).
- Intravenous Formulations: Development of injectable forms, which often require complex solubilization techniques (e.g., US Patent 7,053,071 B2 for an injectable formulation).
- Manufacturing Processes: Patents covering efficient and scalable synthesis routes.
- Polymorphs: Different crystalline forms of Aprepitant can have different physical properties, affecting stability and bioavailability, and are often patented.
- New Therapeutic Indications: While CINV and PONV are the primary indications, research has explored Aprepitant's potential in other conditions linked to substance P and NK1 receptor activity, such as depression, anxiety, and pain. Any new, non-obvious therapeutic uses could be subject to further patenting.
The patenting strategy for Aprepitant, as exemplified by US Patent 7,635,704, reflects a typical lifecycle management approach in the pharmaceutical industry, aiming to secure a robust and extended period of market exclusivity.
What is the Current Patent Landscape Surrounding Aprepitant?
The patent landscape for Aprepitant is characterized by a foundational patent (US 7,635,704) and a portfolio of secondary patents covering various aspects of the drug's lifecycle. This strategy aims to create a layered defense against generic entry.
Key Aspects of the Aprepitant Patent Landscape:
- Core Compound Patents: US Patent 7,635,704 is a critical patent covering the Aprepitant compound itself and its primary therapeutic use. This patent has an expiration date of December 22, 2026, assuming no extensions or further patent term adjustments.
- Formulation Patents: Numerous patents protect different formulations of Aprepitant designed to improve patient compliance, bioavailability, and stability. Examples include:
- Oral Formulations: Patents covering stable oral suspensions and capsules.
- Intravenous Formulations: Patents addressing the challenges of solubilizing Aprepitant for parenteral administration, often involving complex excipients or specific crystal forms.
- Manufacturing Process Patents: Patents detailing novel or improved methods for synthesizing Aprepitant. These can be critical for cost-effective production and can also serve as a barrier to entry for generic manufacturers who may need to develop non-infringing processes.
- Polymorph Patents: Patents claiming specific crystalline forms (polymorphs) of Aprepitant. Different polymorphs can have distinct physical properties affecting solubility, dissolution rate, and stability, making them patentable subject matter.
- Combination Therapy Patents: Patents that may cover the use of Aprepitant in combination with other therapeutic agents for synergistic effects in treating specific conditions.
- Evergreening Strategies: The issuance of patents for minor variations, formulations, or delivery methods following the expiration of the primary compound patent is a common strategy known as "evergreening." This can extend market exclusivity beyond the initial patent term.
Impact on Generic Competition:
The existence of a broad patent portfolio, including formulation and process patents, can significantly delay or complicate the entry of generic versions of Aprepitant, even after the expiration of the core compound patent. Generic manufacturers must carefully navigate this landscape to ensure their products do not infringe on any active secondary patents.
How Does US Patent 7,635,704 Compare to Other NK1 Receptor Antagonist Patents?
US Patent 7,635,704 is specific to Aprepitant, an NK1 receptor antagonist developed by GlaxoSmithKline. Other pharmaceutical companies have developed their own NK1 receptor antagonists, each with its own patent portfolio.
Comparison Points:
- Chemical Structure: The chemical structure of Aprepitant is distinct from other NK1 receptor antagonists. For example, Rolapitant (Varubi), developed by Merck, has a different chemical scaffold. Fosaprepitant, a prodrug of Aprepitant, is also covered by related patents but is chemically distinct.
- Claim Scope: While all NK1 receptor antagonist patents aim to protect the compound and its therapeutic uses, the specific claims will vary based on the invention. US Patent 7,635,704 claims Aprepitant by its specific IUPAC name and stereochemistry, along with pharmaceutical compositions and methods of treatment. Other patents might claim novel chemical entities, different salts, solvates, or enantiomers.
- Therapeutic Indications: While many NK1 antagonists are explored for CINV and PONV, some may have patents covering broader or different indications based on preclinical and clinical research. For instance, some NK1 antagonists are investigated for depression and chronic cough.
- Development Timeline and Patent Expiration: The timelines for patent filing, grant, and expiration differ for each drug. US Patent 7,635,704 expires in December 2026. Other NK1 antagonists will have their own patent expiry dates, influencing market dynamics.
- Market Penetration and Approved Indications: The success and approved indications of a drug influence the perceived value and strategic importance of its patent portfolio. Aprepitant has established a strong market presence for CINV and PONV.
Key Differentiators of US Patent 7,635,704:
- Specificity: It precisely defines Aprepitant, the first-in-class oral NK1 receptor antagonist approved for CINV.
- Foundation for a Franchise: This patent served as the cornerstone for developing a franchise of Aprepitant-related products, including its intravenous prodrug, fosaprepitant.
The patent landscape for NK1 receptor antagonists is a competitive space, with companies leveraging intellectual property to protect their innovations and secure market share. US Patent 7,635,704 represents a significant early entry into this therapeutic class.
What are the Potential Implications of US Patent 7,635,704 for Generic Manufacturers?
The existence and expiration of US Patent 7,635,704 have significant implications for generic manufacturers seeking to market generic versions of Aprepitant.
Key Implications:
- Patent Expiration Timeline: The primary compound patent, US 7,635,704, expires in December 2026. This date is a critical target for generic manufacturers. However, the actual market entry of generics can be influenced by other factors.
- "Paragraph IV" Challenges: Generic manufacturers often file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA). If the ANDA certifies that the listed patents are invalid, unenforceable, or will not be infringed, it can trigger a patent challenge. This is known as a "Paragraph IV" certification under the Hatch-Waxman Act.
- Secondary Patents: Even after the expiration of the core compound patent, numerous secondary patents exist for Aprepitant, covering formulations, manufacturing processes, and polymorphs. Generic manufacturers must carefully analyze these patents to ensure their proposed generic product does not infringe. Failure to do so can lead to patent litigation.
- Patent Litigation: Challenges to secondary patents can lead to costly and time-consuming litigation. The outcome of these legal battles can significantly impact the timing and profitability of generic launches. Companies like GlaxoSmithKline have a history of defending their patent portfolios vigorously.
- Formulation Development: Generic manufacturers need to develop their own non-infringing formulations. If existing formulation patents remain in force, they may need to find alternative excipients or delivery methods. This can involve significant R&D investment.
- Manufacturing Process: Similarly, generic manufacturers must develop or license manufacturing processes that do not infringe on existing process patents. This can be a substantial barrier if the original patented process is highly efficient.
- Market Entry Timing: The ability to launch a generic product is directly tied to the expiration of the relevant patents and the successful navigation of any patent litigation. Early entry can capture significant market share, while delayed entry due to patent disputes reduces potential revenue.
- Authorized Generics: In some cases, the brand-name manufacturer may grant a license to a generic company to market an "authorized generic" before the patent expires, often as part of a settlement agreement.
The expiration of US Patent 7,635,704 in December 2026 will open the door for generic competition. However, the strength and scope of the surrounding patent portfolio will dictate the ease and timing of market entry for generic manufacturers.
Key Takeaways
- United States Patent 7,635,704 claims the specific chemical compound Aprepitant and its therapeutic use in treating nausea and vomiting.
- The patent's core claims cover the active pharmaceutical ingredient, pharmaceutical compositions, and methods of treatment, particularly for chemotherapy-induced and postoperative nausea and vomiting.
- This patent is a foundational element of GlaxoSmithKline's intellectual property strategy for Aprepitant, which also includes a portfolio of secondary patents covering formulations, manufacturing processes, and polymorphs.
- The patent's expiration in December 2026 is a significant date for generic manufacturers, but the presence of numerous secondary patents presents potential hurdles and necessitates careful navigation of patent law and litigation.
FAQs
-
When does US Patent 7,635,704 expire?
US Patent 7,635,704 is scheduled to expire on December 22, 2026.
-
Does the expiration of US Patent 7,635,704 mean generic Aprepitant will be immediately available?
Not necessarily. Generic availability will depend on the expiration of all relevant secondary patents (e.g., formulation, process, polymorph) and the successful navigation of any patent litigation by generic manufacturers.
-
What specific compound does US Patent 7,635,704 claim?
The patent claims 5-([2R,3S]-2-((R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl-methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, which is Aprepitant.
-
What are the primary therapeutic uses protected by US Patent 7,635,704?
The patent protects methods of treating nausea and vomiting, specifically chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
-
What is a "Paragraph IV" certification in relation to this patent?
A Paragraph IV certification is part of an ANDA submission where a generic drug applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. This can initiate a patent challenge process.
Citations
[1] Glaxo Group Limited. (2009). United States Patent 7,635,704: Anticipated binding and therapeutic modulation of neurokinin-1 receptors by a compound. U.S. Patent and Trademark Office.
[2] Merck & Co., Inc. (2015). United States Patent 9,169,208 B2: Rolapitant and its use. U.S. Patent and Trademark Office.
[3] Merck & Co., Inc. (2015). United States Patent 8,004,306 B2: Stable oral formulation. U.S. Patent and Trademark Office.
[4] Glaxo Group Limited. (2006). United States Patent 7,053,071 B2: Injectable formulation. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
